Abstract:Background: Over the past two decades, the Food and Drug Administration (FDA) has significantly increased the approval of anti−obesity medications (AOMs) for obesity management. Both FDA−approved AOMs (F−AOMs) and off−label AOMs (O−AOMs) have gained popularity and demonstrated promising results in randomized clinical trials (RCTs). However, their effectiveness in real−world settings remains less understood. In this study, we evaluated population−level responses to AOMs and individual variability under real−world conditions, leveraging electronic health records (EHRs) as the primary data source for a comprehensive analysis of obesity relevant metrics. Methods: EHRs of patients with obesity or overweight diagnosis were retrieved from the University of Texas Physician (UT−Physician) and EPIC COSMOS database. F−AOMs and O−AOMs were analyzed for their effects on obesity relevant metrics including body weight, body mass index (BMI), blood pressure (BP), high−density lipoprotein (HDL), low−density lipoprotein (LDL), HbA1c, and triglyceride levels. Results: From the UT−Physician (U) and COSMOS (C) datasets, we identified 444K (2005−2023) and 30M (2018−2023) patients as obese or overweight, respectively. Of these, 72,089 (6.2%) and 10M (~30%) had exposure to AOMs. During the study period, [U:37%; C:48%] of patients underwent more than one treatment session. The median exposure time to F−AOMs are [U:2.9; C:6.1] months. The median exposure time to O−AOMs are [U:2.9; C:14] months. For both cohorts, F−AOMs generally showed superior weight loss effects than O−AOMs. Tirzepatide and semaglutide were the most effective F−AOMs. Tirzepatide achieved 5% and 10% weight loss respectively in [U:65%; C:63%] and [U:33%; C:42%] of patients on long−term [U:76 wks; C:79 wks] exposure. Semaglutide achieved 5% and 10% weight loss respectively in [U:37%; C:45%] and [U:16%; C:25%] of patients on long−term [U:94 wks; C:88 wks] exposure. Both medications also benefited HDL, LDL, triglyceride, and HbA1c levels. Among O−AOMs, metformin demonstrated the most effective long−term [U:143 wks; C:166 wks] results, with [U:27%; C:32%] and [U:9%; C:14%] of patients achieving 5% and 10% weight loss, respectively. Significant individual variability in response was observed across all AOMs, irrespective of diagnosis type or exposure duration. Weight gain was noted in a subset of patients, ranging from [U:15%; C:18%] for tirzepatide (long−term) to [U:59%; C:62%] for lisdexamfetamine (long−term). Significant weight regain was consistently observed in both cohorts after discontinuing phentermine series, zonisamide, topiramate, and lisdexamfetamine. Conclusions: Remarkable differences were observed between real−world evidence from EHR data and RCT reports on AOM effectiveness, highlighting the challenges of applying RCT results to diverse populations in routine practice. The wide variation in individual responses to both FDA−approved and off−label AOMs underscores the importance of personalizing obesity treatment to improve effectiveness, support long−term adherence, and promote sustainable care strategies.

The association between weight loss medications and cardiovascular complications

The weight reduction mediated by anti-obesity medication and the cardiovascular outcome

The impact of approved anti-obesity medications on osteoarthritis

Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database

Medications for Obesity: A Review

Current status of anti-obesity medications and performance, an EHR based survey

Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience

Nutritional considerations with antiobesity medications

Pharmacologic management of obesity: Updates on approved medications, indications and risks

The association between previous use of anti‐obesity medication and semaglutide weight loss outcomes

Anti-obesity medications in the management of heart failure with preserved ejection fraction: available evidence and next STEPS

1684-P: CONCRETE—Characterization of Patients Receiving Telemedicine and Branded Antiobesity Medication for Medical Weight Management—A Retrospective Analysis

Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery

Association of patient characteristics and insurance type with anti‐obesity medications prescribing and fills

Effectiveness and safety of drugs for obesity

Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.)

Twelve‐month analysis of real‐world evidence from a telehealth obesity‐treatment provider using antiobesity medications

Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions

Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management

Do People Reduce Attempts At Lifestyle Change After Initiating Weight Loss Medication? A Review Of Trial Evidence

Gastrointestinal Adverse Events Associated with Popular Antiobesity Drugs